Results 91 to 100 of about 219,094 (347)

Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint 
Inhibitor Therapy

Chinese Journal of Lung Cancer, 2022
Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody ...
Liyuan DAI, Xiaohong HAN
doaj   +1 more source

Variable domain N-linked glycosylation and negative surface charge are key features of monoclonal ACPA: implications for B-cell selection [PDF]

, 2018
Autoreactive B cells have a central role in the pathogenesis of rheumatoid arthritis (RA), and recent findings have proposed that anti-citrullinated protein autoantibodies (ACPA) may be directly pathogenic. Herein, we demonstrate the frequency of variable-region glycosylation in single-cell cloned mAbs.
arxiv   +1 more source

Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study

BMJ Open, 2016
Introduction Type 1 diabetes can be diagnosed at an early presymptomatic stage by the detection of islet autoantibodies. The Fr1da study aims to assess whether early staging of type 1 diabetes (1) is feasible at a population-based level, (2) prevents ...
J. Raab, F. Haupt, Marlon Scholz, Claudia Matzke, K. Warncke, K. Lange, R. Assfalg, Katharina Weininger, Susanne Wittich, Stephanie Löbner, A. Beyerlein, U. Nennstiel-Ratzel, M. Lang, O. Laub, D. Dunstheimer, E. Bonifacio, P. Achenbach, C. Winkler, A. Ziegler   +18 more
semanticscholar   +1 more source

CSF Tau Is a Biomarker of Hippocampal Injury in Cryptogenic New‐Onset Refractory Status Epilepticus

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cryptogenic new‐onset refractory status epilepticus (cNORSE) is a devastating condition characterized by the de novo onset of status epilepticus with unclear etiology. The identification of relevant early biomarkers in cNORSE is important to elucidate pathophysiology, aid clinical decision‐making, and prognosticate outcomes in cNORSE.
Yihui Goh, Yoonhyuk Jang, Soo Jean Shin, Soo Hyun Ahn, Su Yee Mon, Yoon Hee Shin, Kon Chu, Sang Kun Lee, Soon‐Tae Lee   +8 more
wiley   +1 more source

Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer

OncoImmunology, 2017
Identification of biomarkers for early detection of lung cancer (LC) is important, in turn leading to more effective treatment and reduction of mortality.
Liping Dai, Jitian Li, Jun-Chieh J. Tsay, Ting-An Yie, John S. Munger, Harvey Pass, William N. Rom, Eng M. Tan, Jian-Ying Zhang   +8 more
doaj   +1 more source

Differential genetic associations for systemic lupus erythematosus based on anti-dsDNA autoantibody production.

PLoS Genetics, 2011
Systemic lupus erythematosus (SLE) is a clinically heterogeneous, systemic autoimmune disease characterized by autoantibody formation. Previously published genome-wide association studies (GWAS) have investigated SLE as a single phenotype.
Sharon A Chung, Kimberly E Taylor, Robert R Graham, Joanne Nititham, Annette T Lee, Ward A Ortmann, Chaim O Jacob, Marta E Alarcón-Riquelme, Betty P Tsao, John B Harley, Patrick M Gaffney, Kathy L Moser, SLEGEN, Michelle Petri, F Yesim Demirci, M Ilyas Kamboh, Susan Manzi, Peter K Gregersen, Carl D Langefeld, Timothy W Behrens, Lindsey A Criswell   +20 more
doaj   +1 more source

The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia

Rheumatology, 2017
Objectives Autoantibody testing is helpful for predicting the risk of progression to clinical arthritis in subjects at risk. Previous longitudinal studies have mainly selected autoantibody-positive arthralgia patients, and consequently the predictive ...
R. M. ten Brinck, H. V. van Steenbergen, M. V. van Delft, M. Verheul, R. Toes, L. Trouw, A. H. van der Helm - van Mil   +6 more
semanticscholar   +1 more source

ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib, Kristl G. Claeys, Vera Bril, Yessar Hussain, Kelly Gwathmey, Gregory Sahagian, Elena Cortés‐Vicente, Edward Brauer, Deborah Gelinas, Anne Sumbul, Rosa H. Jimenez, Daniela Hristova, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Shahram Attarian, On behalf of the ADAPT NXT Study Group   +16 more
wiley   +1 more source

Function of B cells expressing a human immunoglobulin M rheumatoid factor autoantibody in transgenic mice. [PDF]

, 1993
We have generated transgenic mice that express the immunoglobulin (Ig)M heavy chain and kappa light chain genes coding for a human IgM rheumatoid factor (RF), Les.
Carson, DA, Chen, PP, Jirik, FR, Kipps, TJ, Roudier, J, Tighe, H, Tucker, R   +6 more
core  

Cytokine and autoantibody clusters interaction in systemic lupus erythematosus

Journal of Translational Medicine, 2017
BackgroundEvidence supports the existence of different subphenotypes in systemic lupus erythematosus (SLE) and the pivotal role of cytokines and autoantibodies, which interact in a highly complex network.
Y. Pacheco, Julián Barahona-Correa, D. Monsalve, Y. Acosta-Ampudia, M. Rojas, Yhojan Rodríguez, Juliana Saavedra, M. Rodríguez-Jimenez, R. Mantilla, C. Ramírez-Santana, N. Molano-González, J. Anaya   +11 more
semanticscholar   +1 more source